Four new drugs will change prostate cancer care

After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer a chronic illness instead of a terminal disease, a leading Colorado prostate cancer expert says.

"It's not just chemotherapy. The drugs have different and innovative methods of action. One is a bone protective agent; another's a more effective hormone agent; another is radiotherapy; and the final one is the first drug tested for ," says E. David Crawford, MD, investigator at the University of Colorado Cancer Center and head of urologic oncology at University of Colorado Hospital.

"Even without the addition of any more drugs, we may now have the tools that in combination will allow us to extend the survival prognosis of a patient long enough to make prostate cancer a disease a patient is more likely to die with than from," Crawford says.

Along with Thomas Flaig, MD, Crawford describes these advances in in a recent review for the journal Oncology.

First is the drug Denosumab, which Crawford says, "has three uses in protecting the bones of prostate cancer patients." It can prevent in patients with existing bone metastasis; it can prevent osteoporosis in patients whose calcium is depleted as a side-effect of hormone therapy; and (pending ) it has been shown to hold off the occurrence of bone metastasis for an average of four months in patients whose spiking PSA scores predict the likely onset of bone involvement.

Second is the drug Alpharadin, which is one of a novel and exciting class of "radiopharmaceuticals" – drugs that emit radiation and allow doctors to precisely deliver radiation to tumor sites. In the case of Alpharadin, it emits alpha rather than beta particles, which allows more precise tumor targeting of sites with less collateral damage to surrounding bone marrow.

Third, the drug Prostvac is the first "immunotherapy" drug used for the treatment of cancer. The drug acts like a vaccine, priming the immune system to recognize and thus fight against prostate cancer cells. In a phase II clinical trial of 125 patients, the drug extended the median survival time from 16.6 to 25.1 months.

Finally, the drug Abiraterone Acetate completely suppresses the body's ability to make testosterone, which many prostate cancers need to grow (as opposed to previous drugs, which hoped to out-compete testosterone with estrogen, or imperfectly controlled testosterone production).

Crawford notes that these drugs are being approved for use only after more established therapies have failed and hopes that in coming years science may accelerate the use of these drugs to first-line therapies.

E. David Crawford, MD, investigator at the University of Colorado Cancer Center

"Before we just had hormone therapy, then we got chemo, and each therapy we added packed on another couple months of survival. Now with these news drugs we're tacking on even more time. The light at the end of the tunnel is the hope that we'll turn this into a chronic disease and now we might have the tools that in some combination will do it," Crawford says.

Provided by University of Colorado Denver

3.3 /5 (13 votes)

Related Stories

First Phase III trial of an alpha-pharmaceutical

Sep 23, 2011

Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong ...

Recommended for you

Unraveling the 'black ribbon' around lung cancer

Apr 17, 2014

It's not uncommon these days to find a colored ribbon representing a disease. A pink ribbon is well known to signify breast cancer. But what color ribbon does one think of with lung cancer?

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

MyPhysorgID
not rated yet Feb 17, 2012
I am appalled, frankly, that an article of this nature and scope would ignore the revolutionary treatment Provenge for end stage prostate cancer. Intended for men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer, the treatment provides a 4.1-month median life extension benefit. Recent analyses presented at 2011 ASCO and 2012 GU, however, took into the account the crossovers from the placebo cohort that were given a frozen form of Provenge called Frovenge. With these patients removed from the cohort, the median life extension benefit for Provenge was found to range between 7.8 and 12.1 months. How a treatment such as Provenge escaped this author is beyond comprehension. There is nothing on the market or even close to market today that provides such a benefit to men as does Provenge.
ocyan
not rated yet Feb 17, 2012
Dr. Crawford, you mistook "Prostvac" for "Provenge". Provenge is an immunotherapy that has been approved by the FDA and is being used to treat patients with minimally symptomatic metastatic prostate cancer. "Prostvac" is still being tested in a phase-3 trial whose results will not be known for a few years.